---
title: "605369.SH (605369.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/605369.SH/news.md"
symbol: "605369.SH"
name: "605369.SH"
parent: "https://longbridge.com/en/quote/605369.SH.md"
datetime: "2026-05-20T16:51:06.707Z"
locales:
  - [en](https://longbridge.com/en/quote/605369.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/605369.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/605369.SH/news.md)
---

# 605369.SH (605369.SH) — Related News

### [Gongdong Medical: Change of Financial Responsible Person, Zhu Yong Resigns and Guo Senhao Takes Over](https://longbridge.com/en/news/284169953.md)
*2026-04-27T07:38:23.000Z*
> Gongdong Medical announced that on April 27, Zhu Yong resigned from the position of financial director due to work adjus

### [Gongdong Medical released its first-quarter performance, with a net profit attributable to the parent company of 31.99 million yuan, a year-on-year increase of 16.71%](https://longbridge.com/en/news/283869691.md)
*2026-04-23T16:52:03.000Z*
> Gongdong Medical released its Q1 2026 performance, with revenue of 289 million yuan, a year-on-year increase of 9.12%; n

### [Zhiran Medical has secured another 300 million yuan in A+ round financing within six months, accelerating the clinical implementation of invasive brain-machine interfaces](https://longbridge.com/en/news/275532854.md)
*2026-02-11T01:17:18.000Z*
> Zhiran Medical recently completed a 300 million yuan A+ round of financing, led by Thundersoft. The funds will be used t

### ["ZhiRan Medical" secures another 300 million yuan in Series A+ financing, plans to launch large-scale registered clinical trials in 2026 | 36Kr Exclusive](https://longbridge.com/en/news/275534330.md)
*2026-02-11T01:17:10.000Z*
> Zhiran Medical has secured 300 million yuan in Series A+ financing, led by Zhongke Chuangxing, with existing shareholder

### [Gongdong Medical has obtained the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment (CNAS)](https://longbridge.com/en/news/274480448.md)
*2026-02-02T07:56:23.000Z*
> Gongdong Medical recently obtained the laboratory accreditation certificate granted by the China National Accreditation 

### [Gongdong Medical issued a profit warning, expecting a year-on-year decrease of 67.37% to 74.36% in net profit attributable to the parent company for the fiscal year 2025](https://longbridge.com/en/news/273486391.md)
*2026-01-23T08:31:03.000Z*
> Gongdong Medical released its annual performance forecast for 2025, expecting the net profit attributable to the owners 

### [Gongdong Medical: Shi Huiyong and Jin Chi Investment collectively reduced their holdings by 6,607,240 shares, with the shareholding ratio decreasing to 61.21%](https://longbridge.com/en/news/269835377.md)
*2025-12-16T08:54:37.000Z*
> Gongdong Medical announced that its controlling shareholder Shi Huiyong reduced his holdings by 4,402,400 shares through

### [Gongdong Medical: Shareholding reduction by shareholders holding over 5% leads to a change in equity reaching 1%](https://longbridge.com/en/news/263705375.md)
*2025-10-31T09:52:32.000Z*
> Gongdong Medical announced that its shareholder Taizhou Jinch Investment Management Partnership will reduce its holdings

### [Gongdong Medical's controlling shareholders plan to reduce their holdings by no more than 3%](https://longbridge.com/en/news/255936292.md)
*2025-09-04T10:35:42.000Z*
> According to the announcement from Dolphin Research, Gongdong Medical stated that within three months after the 15 tradi